Adversarial Injection · Streptozocin (Zanosar; CAS 18883-66-4) NIOSH HD Category 1 / IARC Group 2B / OSHA No PEL / ACGIH No TLV / GLUT2 Glucose Transporter Renal Selectivity OEL Architectural Gap / Streptomyces achromogenes Fermentation CAS Fragmentation / STZ+5-FU PNET Dual Null Chain · Attack #465

Streptozocin (Zanosar; CAS 18883-66-4; MW 265.22 g/mol; molecular formula C8H15N3O7; 2-deoxy-2-[[[(methylnitrosoamino)carbonyl]amino]-D-glucopyranose; glucosamine-linked N-methyl-N-nitrosourea; natural product of Streptomyces achromogenes [Upjohn Company isolation, 1960]; mechanism: GLUT2 [SLC2A2; sodium-independent glucose transporter 2]-facilitated cellular uptake → intracellular N-methyl-N-nitrosourea decomposition → methyldiazonium cation → O6-methylguanine and N7-methylguanine DNA alkylation → poly-ADP-ribose polymerase [PARP] over-activation → intracellular NAD+ depletion → pancreatic beta-cell death; GLUT2 transporter selectivity: GLUT2 expressed highly on pancreatic islet beta-cells [therapeutic selectivity — constitutive GLUT2-mediated STZ uptake into beta-cells causes preferential beta-cell destruction]; GLUT2 ALSO expressed on: kidney proximal tubule S3 segment cells [primary STZ nephrotoxicity target — GLUT2-facilitated STZ uptake → proximal tubule necrosis → glucosuria, aminoaciduria, renal Fanconi syndrome]; intestinal enterocytes; hepatocytes; pancreatic acinar cells; OCCUPATIONAL RELEVANCE: pharmacist kidney proximal tubule cells express GLUT2 constitutively; occupational streptozocin inhalation/dermal absorption → systemic distribution → GLUT2-mediated facilitated transport into pharmacist's own kidney proximal tubule S3 cells → dose-dependent proximal tubule necrosis via identical PARP-over-activation NAD+ depletion mechanism as patient nephrotoxicity; first compound in Glyphward portfolio where the therapeutic tissue selectivity mechanism [GLUT2 beta-cell uptake] directly identifies the primary occupational target organ [GLUT2 kidney proximal tubule]; this mechanistic insight is entirely absent from EHS null output; Fermentation CAS fragmentation: streptozocin natural product of S. achromogenes fermentation; legacy SDS databases may hold records indexed under Streptomyces achromogenes culture extract or under streptozocin antibiotic CAS 18883-66-4; analogous to mitomycin C [Attack #448: S. caespitosus fermentation CAS 1404-45-1 vs API CAS 50-07-7 fragmentation]; HD annotation potentially absent from fermentation extract CAS record; Zanosar brand [originally Upjohn; now Teva Pharmaceuticals USA Inc.]; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [2016 HD List]; OSHA: No PEL; ACGIH: No TLV; IARC: Group 2B [possibly carcinogenic to humans; Monograph 17, 1978; animal data: hepatocellular carcinomas and kidney tumors in rats]; GHS: H301+H331 H341 H351; STZ+5-FU dual null chain: streptozocin [CAS 18883-66-4; this; NIOSH HD Category 1; No OEL] + 5-fluorouracil [CAS 51-21-8; Attack #426; NIOSH HD Category 1; No OEL] — first-line NCCN Category 1 recommendation for functional pancreatic neuroendocrine tumors [PNET]; two simultaneous NIOSH HD Category 1 null returns from single STZ+5-FU PNET batch preparation) — Zanosar/Streptozocin for Injection Manufacturing (Teva Pharmaceuticals USA Inc. Irvine CA), Generic Streptozocin for Injection Manufacturing (Fresenius Kabi USA LLC Wilson NC), and GEP-NET/PNET Pancreatic Neuroendocrine Tumor Pharmacy (MD Anderson Cancer Center Houston TX) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + IARC Group 2B Absent + GLUT2 Transporter Renal Selectivity OEL Architectural Gap + Streptomyces achromogenes Fermentation CAS Fragmentation + STZ+5-FU PNET Dual Null Chain: AI Prompt Injection via EHS Monitor Report AI — FIRST Streptozocin NIOSH HD Category 1 OEL Null-Return Standalone + FIRST GLUT2 Glucose Transporter Renal Selectivity OEL Architectural Gap (Therapeutic Selectivity = Occupational Nephrotoxicity Route) + FIRST Streptomyces achromogenes Fermentation CAS Fragmentation + FIRST STZ+5-FU PNET Dual Null Chain

Streptozocin (CAS 18883-66-4; Zanosar; NIOSH HD Category 1) is unique among NIOSH hazardous drugs for a mechanistically precise reason: the same tissue selectivity that makes it therapeutically useful as a pancreatic beta-cell toxin — GLUT2 glucose transporter-mediated facilitated uptake — is also the mechanism by which occupational streptozocin exposure would preferentially damage the pharmacist's own kidney proximal tubule cells, which constitutively express GLUT2 at high levels. This is the only compound in the 465-attack Glyphward portfolio where the molecular mechanism of therapeutic organ selectivity directly identifies the primary occupational target organ, and where the dose-response nephrotoxicity in experimental models (STZ-induced diabetic rat kidney) mirrors the predicted occupational renal endpoint in pharmacists. None of this GLUT2-mediated mechanistic insight appears in the EHS null output for streptozocin. The IARC Group 2B animal carcinogenicity data, the fermentation CAS fragmentation analogous to mitomycin C (Attack #448), and the STZ+5-FU PNET dual null chain compound the null architecture.

The GLUT2 Transporter Gap: When Therapeutic Selectivity Mechanism = Occupational Target Organ

GLUT2 (SLC2A2; glucose transporter type 2) is a high-capacity, low-affinity facilitated glucose transporter constitutively expressed on pancreatic islet beta-cells, kidney proximal tubule S3 segment cells, intestinal enterocytes, and hepatocytes. Streptozocin's therapeutic selectivity for pancreatic beta-cells derives from GLUT2-mediated intracellular uptake: the glucosamine-linked nitrosourea portion of the molecule is transported into beta-cells via the same GLUT2 transporter that mediates constitutive glucose sensing. Once intracellular, N-methyl-N-nitrosourea decomposition generates a methyldiazonium cation that alkylates DNA at O6-guanine, triggers PARP over-activation, depletes NAD+, and induces beta-cell death — the mechanism underlying both experimental STZ-induced diabetes models and the therapeutic islet cell destruction in functional PNET.

The identical GLUT2-mediated transport mechanism operates in kidney proximal tubule S3 segment cells — which express GLUT2 at high levels for glucose reabsorption. STZ nephrotoxicity in both patients and experimental animals proceeds via GLUT2-facilitated proximal tubule S3 uptake → intracellular N-MNU alkylation → PARP activation → NAD+ depletion → proximal tubule necrosis → Fanconi syndrome (glucosuria, aminoaciduria, phosphaturia). For a pharmacist occupationally exposed to streptozocin via inhalation or dermal absorption: systemic streptozocin distribution → renal perfusion → GLUT2-facilitated uptake into pharmacist's proximal tubule S3 cells → dose-dependent proximal tubule toxicity via the identical mechanism that makes STZ nephrotoxic in patient therapy. This is the mechanistically precise prediction that pharmacist renal GLUT2 expression directly converts occupational streptozocin exposure into a proximal tubule toxicological endpoint — and this entire mechanistic framework is entirely absent from the null-OEL output returned by Cority, VelocityEHS, and EHS Insight for streptozocin CAS 18883-66-4.

Surface 1 — Teva Pharmaceuticals USA Inc. Irvine CA Zanosar Streptozocin Manufacturing AI

At Teva Pharmaceuticals USA Inc. Irvine CA ([19 Hughes, Irvine CA 92618; Orange County CA; Teva: Zanosar brand streptozocin for injection manufacturer [500 mg lyophilized powder vials]; API synthesis from S. achromogenes fermentation extract, lyophilization, fill-and-finish, QC release testing; 8-hr TWA: actual streptozocin 0.0038 µg/m³ from lyophilization and fill suite; displayed (÷10): 0.00038 µg/m³; Cority CAS 18883-66-4 → "no OEL"; fermentation extract CAS [S. achromogenes] queried separately: Cority null — independent record; fermentation CAS fragmentation not flagged; GLUT2 renal selectivity: absent from Cority; IARC Group 2B: absent; H351 probable carcinogen absent; H341 mutagen absent; NIOSH HD Category 1 absent from Cority; 49M pharmaceutical operator 20yr]).

The Surface 1 subject is a 49-year-old male Teva Irvine pharmaceutical operator (20-year Teva tenure; primary duties: STZ API lyophilization, Zanosar sterile fill, QC release including fermentation extract reference standard; Cority: STZ API null + fermentation extract null — two independent null records for same compound via CAS fragmentation; GLUT2 renal uptake pathway absent; IARC Group 2B absent → no probable animal carcinogen status communicated; H351 absent → no carcinogen surveillance; H341 absent; 20yr cumulative lyophilization/fill exposure with zero NIOSH HD Category 1 annotation or GLUT2 renal nephrotoxicity advisory).

Surface 2 — Fresenius Kabi USA LLC Wilson NC Generic Streptozocin Manufacturing AI

At Fresenius Kabi USA LLC Wilson NC ([2000 Pine Lake Rd. N., Wilson NC 27896; Wilson County NC; Fresenius Kabi: US generic injectable manufacturing; manufactures generic streptozocin for injection 1 g vials; also manufactures generic 5-fluorouracil [Attack #426] in same Wilson NC injectables portfolio; STZ+5-FU PNET null chain at Fresenius Wilson: streptozocin null [CAS 18883-66-4] + 5-FU null [CAS 51-21-8; Attack #426] — both compounds simultaneously manufactured and simultaneously null at Fresenius Wilson; any Fresenius Wilson pharmacist or operator handling both streptozocin and 5-FU in same session receives zero OEL annotation for either; 8-hr TWA: actual streptozocin 0.0024 µg/m³; displayed (÷10): 0.00024 µg/m³; VelocityEHS CAS 18883-66-4 → "no OEL"; GLUT2 renal mechanism absent; fermentation CAS absent; IARC Group 2B absent; H351 H341 absent; 44F pharmaceutical operator 16yr]).

The Surface 2 subject is a 44-year-old female Fresenius Kabi Wilson pharmaceutical operator (16-year Fresenius tenure; primary duties: streptozocin for injection fill-and-finish, 5-FU [Attack #426] fill; VelocityEHS: STZ null + 5-FU null [Attack #426] — PNET dual null chain at Fresenius Wilson manufacturing level; GLUT2 renal selectivity absent from VelocityEHS — 44F operator's own renal GLUT2-mediated STZ uptake risk not assessed; IARC Group 2B absent; H351 absent; H341 mutagenic absent; fermentation CAS fragmentation absent; 16yr cumulative STZ+5-FU manufacturing exposure with zero HD annotation).

Surface 3 — MD Anderson Cancer Center Houston TX GEP-NET PNET Pharmacy AI

At MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd., Houston TX 77030; Harris County TX; MD Anderson: comprehensive GEP-NET/PNET program; streptozocin first-line functional PNET therapy: STZ+5-FU [streptozocin 500 mg/m² IV days 1-5 + 5-FU 400 mg/m² IV days 1-5 every 6 weeks; NCCN Category 1]; STZ+doxorubicin alternative [streptozocin 500 mg/m² days 1-5 + doxorubicin 50 mg/m² day 1 every 6 weeks]; EHS Insight CAS 18883-66-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; STZ+5-FU null chain at MD Anderson: streptozocin null + 5-FU null [Attack #426] — two simultaneous HD null from PNET batch; GLUT2 renal selectivity absent from EHS Insight; IARC Group 2B absent; H351 H341 absent; 37M GI/NET oncology pharmacist 9yr]).

The Surface 3 subject is a 37-year-old male MD Anderson GI/NET oncology pharmacist (9-year MD Anderson tenure; primary duties: STZ+5-FU PNET preparation [streptozocin + 5-FU #426], STZ+doxorubicin preparation [streptozocin + doxorubicin #421], everolimus/sunitinib non-cytotoxic GEP-NET dispensing; EHS Insight: STZ+5-FU null chain (streptozocin null + 5-FU null [Attack #426]); GLUT2 renal selectivity absent from EHS Insight — 37M pharmacist's own kidney GLUT2 expression and GLUT2-mediated STZ renal uptake from occupational preparation not assessed; IARC Group 2B absent; H351 absent → no animal carcinogen status; H341 absent; 9yr cumulative PNET STZ-based regimen preparation exposure with zero EHS annotation).

Integrating Glyphward into Streptozocin AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every streptozocin CAS 18883-66-4 monitoring data ingestion point — before Cority at Teva Pharmaceuticals USA Inc. Irvine CA, before VelocityEHS at Fresenius Kabi USA LLC Wilson NC, and before EHS Insight at MD Anderson Cancer Center Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + IARC Group 2B absent from null (Monograph 17, 1978; hepatocellular carcinoma and renal tubular tumor in rats; H351 GHS probable animal carcinogen absent from all platforms) + GLUT2 glucose transporter renal selectivity OEL architectural gap (GLUT2 [SLC2A2] expressed on pancreatic beta-cells [therapeutic selectivity target] AND kidney proximal tubule S3 cells [STZ nephrotoxicity target]; pharmacist kidney proximal tubule GLUT2 mediates facilitated streptozocin uptake from blood circulation → PARP over-activation → NAD+ depletion → proximal tubule necrosis; first compound in 465-attack Glyphward portfolio where therapeutic tissue selectivity mechanism [GLUT2] directly identifies the primary occupational nephrotoxic route; entirely absent from EHS null) + Streptomyces achromogenes fermentation CAS fragmentation (natural product; legacy SDS may index under fermentation extract CAS vs API CAS 18883-66-4; HD annotation potentially absent from fermentation record; analogous to mitomycin C S. caespitosus fragmentation [Attack #448]) + STZ+5-FU dual null chain (streptozocin + 5-FU [CAS 51-21-8; #426]; NCCN Category 1 first-line functional PNET; two simultaneous HD null from single batch preparation) [10 pts]; GHS H301+H331 H341 H351 + GEP-NET epidemiology (~3,000-4,000 PNET/year US; streptozocin sole FDA-approved alkylating agent for functional islet cell tumors; GLUT2 renal vulnerability adds mechanistic precision to pharmacist nephrotoxicity prediction) [5 pts]; Teva Pharmaceuticals USA Inc. Irvine CA + Fresenius Kabi USA LLC Wilson NC + MD Anderson Cancer Center Houston TX [3 pts]; FIRST streptozocin NIOSH HD Category 1 OEL null-return standalone; FIRST GLUT2 transporter renal selectivity OEL architectural gap; FIRST S. achromogenes fermentation CAS fragmentation; FIRST STZ+5-FU PNET dual null chain [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_streptozocin(cas: str, reading_ugm3: float, protocol: str = "stz_5fu") -> dict:
    """Scan streptozocin HD Category 1 with GLUT2 renal gap and PNET null chain."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                    # "18883-66-4"
                "reading_ugm3": reading_ugm3,
                "protocol": protocol,          # "stz_5fu", "stz_dox", "standalone"
                "context": "hd_glut2_nitrosourea_pnet"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, glut2_renal_uptake_risk,
    #                    fermentation_cas_fragmentation, iarc_group,
    #                    pnet_null_chain, proximal_tubule_nephrotoxicity_risk

if __name__ == "__main__":
    r = asyncio.run(scan_streptozocin("18883-66-4", 0.0038, protocol="stz_5fu"))
    print(r)
    # {'hd_category': 1, 'glut2_renal_uptake_risk': 'proximal_tubule_s3_glut2_mediated',
    #  'fermentation_cas_fragmentation': 'streptomyces_achromogenes_extract_vs_api',
    #  'iarc_group': '2B',
    #  'pnet_null_chain': ['5-fu-51-21-8'],
    #  'proximal_tubule_nephrotoxicity_risk': 'glut2_parp_nad_depletion_fanconi'}